- Home
- VNO vs LEGN Comparison
VNO vs LEGN Comparison
Compare VNO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNO
- LEGN
- Stock Information
- Founded
- VNO 1946
- LEGN 2014
- Country
- VNO United States
- LEGN United States
- Employees
- VNO N/A
- LEGN N/A
- Industry
- VNO Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- VNO Real Estate
- LEGN Health Care
- Exchange
- VNO Nasdaq
- LEGN Nasdaq
- Market Cap
- VNO 7.3B
- LEGN 6.7B
- IPO Year
- VNO N/A
- LEGN 2020
- Fundamental
- Price
- VNO $42.98
- LEGN $33.11
- Analyst Decision
- VNO Hold
- LEGN Strong Buy
- Analyst Count
- VNO 11
- LEGN 12
- Target Price
- VNO $38.45
- LEGN $73.36
- AVG Volume (30 Days)
- VNO 1.9M
- LEGN 1.1M
- Earning Date
- VNO 11-03-2025
- LEGN 11-11-2025
- Dividend Yield
- VNO 1.72%
- LEGN N/A
- EPS Growth
- VNO 4453.28
- LEGN N/A
- EPS
- VNO 4.07
- LEGN N/A
- Revenue
- VNO $1,889,783,000.00
- LEGN $796,838,000.00
- Revenue This Year
- VNO N/A
- LEGN $70.75
- Revenue Next Year
- VNO $4.17
- LEGN $52.47
- P/E Ratio
- VNO $10.55
- LEGN N/A
- Revenue Growth
- VNO 0.58
- LEGN 74.75
- 52 Week Low
- VNO $29.68
- LEGN $27.34
- 52 Week High
- VNO $46.63
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- VNO 69.31
- LEGN 36.16
- Support Level
- VNO $39.68
- LEGN $33.20
- Resistance Level
- VNO $41.37
- LEGN $34.71
- Average True Range (ATR)
- VNO 1.00
- LEGN 1.22
- MACD
- VNO 0.51
- LEGN -0.09
- Stochastic Oscillator
- VNO 95.96
- LEGN 10.96
About VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.